The Press Office provides journalists with information on the diverse range of subjects that are relevant to the pharmaceutical industry. Our role is to ensure that any type of media is able to have access to the industry perspective and opinion.
ABPI responds to the new Innovation Scorecard which shows once again unacceptably wide variation in the uptake of NICE-approved medicines in EnglandRead more
Guidance has been published to support charities and pharmaceutical companies in working together to improve the lives of patients.
National Voices and the Association of the British Pharmaceutical Industry have jointly produced a guide on collaboration for both charities and pharmaceutical companies. The guide highlights the benefits that working together can deliver, alongside some of the issues and risks that all parties need to consider. Read more
The Association of the British Pharmaceutical Industry (ABPI), the UK BioIndustry Association (BIA) and the British Generic Manufacturers Association (BGMA) have joined forces to welcome NHS England’s new publication “What is a biosimilar medicine?”.Read more
Alison Clough, acting CEO of the Association of the British Pharmaceutical Industry (ABPI), responds to recent reports in the media on the price of medicines in the UK.Read more
On 17 September 2015, the Association of the British Pharmaceutical Industry (ABPI), in partnership with the Academy of Medical Sciences, held a workshop on ‘real world evidence.’Read more
Dr Virginia Acha, ABPI Executive Director of Research, Medical and Innovation, comments on the vital importance of clinical trial transparency.Read more
Dr Richard Torbett, Executive Director, Commercial at the Association of the British Pharmaceutical Association (ABPI), said: “We welcome this report which sheds an important light on the impact and the sustainability of the Cancer Drugs Fund and we are pleased to have had the opportunity to contribute our views.Read more
David Watson, Director of Pricing and Reimbursement at the ABPI, comments on the Department of Health's new consultation on the statutory scheme.Read more
The ABPI and the Department of Health have today announced a payment of £209 million from industry to underwrite growth of the medicines bill for the second quarter of 2015 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS). Read more
Alison Clough, Acting CEO of the ABPI, responds to NHS England’s announcement that a large number of medicines are to be de-listed from the Cancer Drugs Fund.Read more